3E Bioventures logo

3E Bioventures

Asia, Beijing, China, Beijing

Description

3E Bioventures is a venture capital firm specializing in growth capital.

Investor Profile

3E Bioventures has made 19 investments, with 1 in the past 12 months and 37% as lead.

Stage Focus

  • Series A (58%)
  • Series B (26%)
  • Series C (16%)

Country Focus

  • United States (89%)
  • China (11%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Biopharma
  • Pharmaceutical
  • Health Diagnostics
  • Life Science
  • Medical Device
  • Personal Health
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does 3E Bioventures frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 1
Shangbay Capital
North America, California, United States, Palo Alto
Co-Investments: 2
WuXi Healthcare Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Oceanpine Capital
Asia, Hong Kong Island, Hong Kong, Central
Co-Investments: 2
Virtus Inspire Ventures
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 2
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 2
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 2
SV Tech Ventures
North America, California, United States, Palo Alto
Co-Investments: 2
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 2
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 1

What are some of recent deals done by 3E Bioventures?

Matwings Technology

Minhang, Shanghai, China

Matwings is a biotechnology industry that moves evolution methods to design functionally optimized proteins by leveraging a proprietary.

Alternative ProteinBiotechnologyEnergy Efficiency
Series ANov 15, 2024
Amount Raised: $13,826,478
Arnatar Therapeutics

San Diego, California, United States

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

BiopharmaMedical
Series AApr 8, 2024
Amount Raised: $50,000,000
Myrobalan Therapeutics

Medford, Massachusetts, United States

Myrobalan Therapeutics is a biotech firm that develops oral neurorestorative therapies to reverse key brain dysfunctions and CNS conditions.

BiotechnologyHealth CareTherapeutics
Series AJan 10, 2024
Amount Raised: $24,000,000
Smartlens

Mountain View, California, United States

Clinical stage, novel technologies for managing Glaucoma

Health CareHealth DiagnosticsHome Health CareMedicalMedical DevicePersonal Health
Series AJul 11, 2023
Amount Raised: $6,100,000
Larkspur Biosciences

Watertown, Massachusetts, United States

Larkspur Biosciences is a biotechnology business that is developing the next generation of precision immunotherapies to combat cancer.

BiotechnologyHealth CareMedical
Series AMay 23, 2023
Amount Raised: $35,500,000
Dewpoint Therapeutics

Boston, Massachusetts, United States

Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.

BiotechnologyHealth CareLife ScienceMedicalTherapeutics
Series CFeb 3, 2022
Amount Raised: $150,000,000
Alebund Pharmaceuticals

Shanghai, Shanghai, China

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases.

BiotechnologyLife SciencePharmaceutical
Series BSep 13, 2021
Amount Raised: $54,500,000
NeuralGalaxy

Boston, Massachusetts, United States

NeuralGalaxy is a brain science company which is devoted to solve brain disorders.

Health Care
Series AAug 29, 2021
Amount Raised: $77,258,259
Cullgen

San Diego, California, United States

Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.

BiotechnologyMedicalPharmaceutical
Series BFeb 25, 2021
Amount Raised: $50,000,000
Cardea Bio

San Diego, California, United States

Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.

BiotechnologyInformation TechnologyManufacturingSemiconductor
Series AJan 12, 2021
Amount Raised: $6,500,000